Weyhrauch Derek L, Ye Dan, Boczek Nicole J, Tester David J, Gavrilova Ralitza H, Patterson Marc C, Wieben Eric D, Ackerman Michael J
Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota.
Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic, Rochester, Minnesota.
Pediatr Neurol. 2016 Feb;55:46-51. doi: 10.1016/j.pediatrneurol.2015.10.014. Epub 2015 Nov 6.
A 4-year-old boy born at 37 weeks' gestation with intrauterine growth retardation presented with developmental delay with pronounced language and gross motor delay, axial hypotonia, and dynamic hypertonia of the extremities. Investigations including the Minnesota Newborn Screen, thyroid stimulating hormone/thyroxin, and inborn errors of metabolism screening were negative. Cerebral magnetic resonance imaging and spectroscopy were normal. Genetic testing was negative for coagulopathy, Smith-Lemli-Opitz, fragile X, and Prader-Willi/Angelman syndromes. Whole genome array analysis was unremarkable.
Whole exome sequencing was performed through a commercial testing laboratory to elucidate the underlying etiology for the child's presentation. A de novo mutation was hypothesized. In attempt to establish pathogenicity of our candidate variant, cellular electrophysiologic functional analysis of the putative de novo mutation was performed using patch-clamp technology.
Whole exome sequencing revealed a p.P1353L variant in the CACNA1A gene, which encodes for the α1-subunit of the brain-specific P/Q-type calcium channel (CaV2.1). This presynaptic high-voltage-gated channel couples neuronal excitation to the vesicular release of neurotransmitter and is implicated in several neurologic disorders. DNA Sanger sequencing confirmed that the de novo mutation was absent in both parents and present in the child only. Electrophysiologic analysis of P1353L-CACNA1A demonstrated near complete loss of function, with a 95% reduction in peak current density.
Whole exome sequencing coupled with cellular electrophysiologic functional analysis of a de novoCACNA1A missense mutation has elucidated the probable underlying pathophysiologic mechanism responsible for the child's phenotype. Genetic testing of CACNA1A in patients with congenital hypotonia and developmental delay may be warranted.
一名孕37周出生、患有宫内生长迟缓的4岁男孩,表现出发育迟缓,伴有明显的语言和粗大运动发育迟缓、轴性肌张力减退以及四肢动态性肌张力亢进。包括明尼苏达新生儿筛查、促甲状腺激素/甲状腺素以及先天性代谢缺陷筛查在内的各项检查均为阴性。脑磁共振成像和波谱分析正常。凝血病、史密斯-利姆利-奥皮茨综合征、脆性X综合征以及普拉德-威利/安吉尔曼综合征的基因检测均为阴性。全基因组芯片分析无异常。
通过一家商业检测实验室进行全外显子组测序,以阐明该患儿临床表现的潜在病因。推测存在一个新发突变。为确定候选变异体的致病性,使用膜片钳技术对假定的新发突变进行了细胞电生理功能分析。
全外显子组测序显示,CACNA1A基因存在一个p.P1353L变异,该基因编码脑特异性P/Q型钙通道(CaV2.1)的α1亚基。这种突触前高压门控通道将神经元兴奋与神经递质的囊泡释放相耦合,并与多种神经系统疾病有关。DNA桑格测序证实,父母双方均不存在该新发突变,仅患儿存在。对P1353L-CACNA1A的电生理分析显示功能近乎完全丧失,峰值电流密度降低了95%。
全外显子组测序结合对新发CACNA1A错义突变的细胞电生理功能分析,阐明了导致该患儿表型的可能潜在病理生理机制。对于先天性肌张力减退和发育迟缓患者,可能有必要对CACNA1A进行基因检测。